Search results
Results from the WOW.Com Content Network
Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder. [1] [5] [6] Vibegron is a selective beta-3 adrenergic receptor agonist. [1] The most common side effects include headache, urinary tract infection, common cold, diarrhea, nausea, and upper respiratory tract infection. [5]
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd, announced the publication of a new review of data on Gemtesa (vibegron) 75 mg in the peer-reviewed journal, Therapeutics ...
The chemical structure of vibegron, a β 3-adrenergic receptor agonist. In 2018 two other β 3-AR agonists are in clinical trials, vibegron and solabegron. Vibegron is in phase 3 clinical trial and is used to treat OAB. [3] Solabegron is in phase 2b clinical trials to treat OAB in women and in phase 1 clinical trials in men to treat OAB. [4] [5]
Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder. [1] [2] [3] It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis.
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now. GLP-1s ...
Less-common side effects can include excess air or gas in your stomach, burping, heartburn, indigestion, fast heartbeat, low blood sugar, low energy and fatigue, or even gallstones, Dr. Comite says.
A combination of mirabegron and metformin was studied in mice and caused greater weight loss than either drug alone. [15] A human study in obese individuals found an increase in insulin sensitivity but no significant weight change, which was hypothesized to be due to low levels of BAT in obese humans and/or the low dose of mirabegron used in ...
Solabegron (code name GW-427,353) is a drug which acts as a selective agonist for the β 3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome. [1] [2] [3] It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes. [4] [5]